Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcella Petrone

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
International Journal of Pharmaceutics|January 9, 2020
Developing an injectable co-formulation of two antidiabetic drugs: Excipient impact on peptide aggregation and pharmacokinetic propertiesAnne-Laure Lainé, Sophie Houvenagel, Anders Broo, et al.
Lancet (London, England)|June 28, 2018
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a studyPhilip Ambery, Victoria E Parker, Michael Stumvoll, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2008
New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systemsFabrizio Micheli, Giorgio Bonanomi, Simone Braggio, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluationFabrizio Micheli, Alessandra Pasquarello, Giovanna Tedesco, et al.
Diabetes, Obesity & Metabolism|April 11, 2022
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney diseaseVictoria E R Parker, Thuong Hoang, Heike Schlichthaar, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2008
New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systemsFabrizio Micheli, Giorgio Bonanomi, Simone Braggio, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2019
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon AgonistVictoria E R Parker, Darren Robertson, Tao Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 21, 2013
Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomographyRobert A Comley, Cristian A Salinas, Mark Slifstein, et al.
Neurobiology of Disease|August 25, 2019
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivoDarren J Schofield, Lorraine Irving, Laura Calo, et al.
The Journal of Clinical Investigation|November 7, 2023
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammationMagnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Pharmaceutics|January 9, 2020
Developing an injectable co-formulation of two antidiabetic drugs: Excipient impact on peptide aggregation and pharmacokinetic propertiesAnne-Laure Lainé, Sophie Houvenagel, Anders Broo, et al.
Lancet (London, England)|June 28, 2018
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a studyPhilip Ambery, Victoria E Parker, Michael Stumvoll, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2008
New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systemsFabrizio Micheli, Giorgio Bonanomi, Simone Braggio, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluationFabrizio Micheli, Alessandra Pasquarello, Giovanna Tedesco, et al.
Diabetes, Obesity & Metabolism|April 11, 2022
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney diseaseVictoria E R Parker, Thuong Hoang, Heike Schlichthaar, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2008
New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systemsFabrizio Micheli, Giorgio Bonanomi, Simone Braggio, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2019
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon AgonistVictoria E R Parker, Darren Robertson, Tao Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 21, 2013
Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomographyRobert A Comley, Cristian A Salinas, Mark Slifstein, et al.
Neurobiology of Disease|August 25, 2019
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivoDarren J Schofield, Lorraine Irving, Laura Calo, et al.
The Journal of Clinical Investigation|November 7, 2023
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammationMagnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.
Pageof 3